Lupin inks pact with Exeltis to promote Solosec drug in US

Lupin inks pact with Exeltis to promote Solosec drug in US

AgenciesUpdated: Thursday, January 27, 2022, 09:53 PM IST
article-image
As part of the tie up, Exeltis will promote Solosec along with its existing line of women's health products. |

Lupin stated that its US-based unit has inked a pact with Exeltis Inc to promote Solosec, a drug used to treat bacterial vaginosis in women.

As part of the tie up, Exeltis will promote Solosec along with its existing line of women's health products.

Solosec is indicated for the treatment of bacterial vaginosis in adult women and trichomoniasis in adults, a common non-viral, curable sexually transmitted infection in the US.

''This partnership will expand the reach of Solosec, allowing more healthcare providers to be aware of its benefits, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis,'' stated Lupin CEO Vinita Gupta.

(With inputs from PTI)

RECENT STORIES

FIIs Set For 2026 Comeback, Analysts Forecast Inflows Amid Strong GDP & Earnings Recovery

FIIs Set For 2026 Comeback, Analysts Forecast Inflows Amid Strong GDP & Earnings Recovery

NCLAT Upholds NCLT Order, Rejects Equitas Bank's Insolvency Plea Against Jumbo Finvest

NCLAT Upholds NCLT Order, Rejects Equitas Bank's Insolvency Plea Against Jumbo Finvest

PNB Exposes ₹2,434 Crore Loan Fraud By Former Srei Promoters, Flags Evergreening & Connected...

PNB Exposes ₹2,434 Crore Loan Fraud By Former Srei Promoters, Flags Evergreening & Connected...

Banking Sector Outlook Brightens: Capital Market Company Elara Forecasts Strong Q3 FY26 Loan Growth

Banking Sector Outlook Brightens: Capital Market Company Elara Forecasts Strong Q3 FY26 Loan Growth

SIP Inflows Surge Past ₹3 Lakh Crore First Time In 2025

SIP Inflows Surge Past ₹3 Lakh Crore First Time In 2025